B cell activator factor and a proliferation-inducing ligand at the cross-road of chronic lymphocytic leukemia and autoimmunity

Leukemia and Lymphoma

Volumn 50, Issue 7, 2009, Pages 1075-1082

  Ferrer, Gerardo ^a   Hodgson, Kate ^a   Montserrat, Emili ^a   Moreno, Carol ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Autoimmunity: Responses to self antigen; Cytokine and chemokine biology; Lymphoid leukemia

Indexed keywords

ANTILEUKEMIC AGENT; APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; B CELL MATURATION ANTIGEN; GELONIN; I KAPPA B KINASE ALPHA; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECOMBINANT GELONIN; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; B LYMPHOCYTE DIFFERENTIATION; BINDING SITE; CARCINOGENESIS; CELL MATURATION; CELL METABOLISM; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; RHEUMATOID ARTHRITIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; WALDENSTROEM MACROGLOBULINEMIA;

ANTIGEN-PRESENTING CELLS; ANTIGENS; AUTOIMMUNE DISEASES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; HOMEOSTASIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIGANDS; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 68449091982     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903013334     Document Type: Review

References (86)

1. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008;2008:450-456.
2. Hamblin TJ, Oscier DG, Young BJ. Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 1986;39:713-716.
3. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
4. Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998;188:1185-1190.
5. Ohata J, Zvaifler NJ, Nishio M, et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005;174:864-870.
6. Mackay F, Browning JL. BAFF: A fundamental survival factor for B cells. Nat Rev Immunol 2002;2:465-475.
7. Mackay F, Ambrose C. The TNF family members BAFF and APRIL: The growing complexity. Cytokine Growth Factor Rev 2003;14:311-324.
8. Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol 2006;18:305-317.
9. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007;19:327-336.
10. Ramanujam M, Davidson A. The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res Ther 2004;6:197-202.
11. Ansell SM, Witzig TE, Inwards DJ, et al. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2008;14:1105-1110.
12. Kofler DM, Elter T, Gianella-Borradori A, et al. A phase Ib trial of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed B-cell chronic lymphocytic leukemia (B-CLL) [abstract]. J Clin Oncol 2007;25:18S. Abstract 3029.
13. Ponce R, Miller D. Preclinical support for combination therapy in the treatment of autoimmunity with atacicept. Toxicol Pathol 2009;37:89-99.
14. Schneider P, Mackay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189:1747-1756.
15. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: Novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006;5:235-246.
16. Liu Y, Xu L, Opalka N, Kappler J, Shu HB, Zhang G. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 2002;108:383-394.
17. Oren DA, Li Y, Volovik Y, et al. Structural basis of BLyS receptor recognition. Nat Struct Biol 2002;9:288-292.
18. Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005;201:195-200.
19. Morimoto S, Nakano S, Watanabe T, et al. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: The role of BAFF in T cell-dependent B cell pathogenic autoantibody production. Rheumatology (Oxford) 2007;46:1083-1086.
20. Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001;97:198-204.
21. Scapini P, Nardelli B, Nadali G, et al. G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 2003;197:297-302.
22. Craxton A, Magaletti D, Ryan EJ, Clark EA. Macrophageand dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003;101:4464-4471.
23. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006;118:281-292.
24. Bossen C, Schneider P. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol 2006;18: 263-275.
25. Bodmer JL, Schneider P, Tschopp J. The molecular architecture of the TNF superfamily. Trends Biochem Sci 2002;27:19-26.
26. Kim HM, Yu KS, Lee ME, et al. Crystal structure of the BAFF-BAFF-R complex and its implications for receptor activation. Nat Struct Biol 2003;10:342-348.
27. von Bulow GU, Bram RJ. NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997;278:138-141.
28. Wu Y, Bressette D, Carrell JA, et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BLyS. J Biol Chem 2000;275:35478-35485.
29. Reyes SL, Leon BF, Rozas VM, Gonzalez JP, Naves PR. BAFF: A regulatory cytokine of B lymphocytes involved in autoimmunity and lymphoid cancer. Rev Med Chil 2006;134:1175-1184.
30. Laabi Y, Gras MP, Carbonnel F, et al. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. EMBO J 1992;11:3897-3904.
31. O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004;199:91-98.
32. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179:7276-7286.
33. Salzer U, Jennings S, Grimbacher B. To switch or not to switch - the opposing roles of TACI in terminal B cell differentiation. Eur J Immunol 2007;37:17-20.
34. Xia XZ, Treanor J, Senaldi G, et al. TACI is a TRAFinteracting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation. J Exp Med 2000;192:137-143.
35. Xu S, Lam KP. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001;21:4067-4074.
36. YanM,Wang H, Chan B, et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2001;2:638-643.
37. Fagarasan S, Honjo T. T-Independent immune response: New aspects of B cell biology. Science 2000;290:89-92.
38. Castigli E, Wilson SA, Scott S, et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005;201:35-39.
39. Castigli E, Wilson SA, Garibyan L, et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005;37:829-834.
40. Darce JR, Arendt BK, Wu X, Jelinek DF. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007;179:7276-7286.
41. Bonizzi G, Karin M. The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280-288.
42. Aggarwal BB. Signalling pathways of the TNF superfamily: A double-edged sword. Nat Rev Immunol 2003;3:745-756.
43. He JQ, Zarnegar B, Oganesyan G, et al. Rescue of TRAF3-null mice by p100 NF-κB deficiency. J Exp Med 2006;203: 2413-2418.
44. Xu Y, Cheng G, Baltimore D. Targeted disruption of TRAF3 leads to postnatal lethality and defective T-dependent immune responses. Immunity 1996;5:407-415.
45. Hauer J, Puschner S, Ramakrishnan P, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/ 5-mediated activation of the noncanonical NF-κB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 2005;102:2874-2879.
46. Thien M, Phan TG, Gardam S, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004;20:785-798.
47. Emmerich F, Bal G, Barakat A, et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007; 136:309-314.
48. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002;3:424-429.
49. Koyama T, Tsukamoto H, Masumoto K, et al. A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology (Oxford) 2003;42:980-985.
50. Koyama T, Tsukamoto H, Miyagi Y, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005;64:1065-1067.
51. Lee YH, Ota F, Kim-Howard X, Kaufman KM, Nath SK. APRIL polymorphism and systemic lupus erythematosus (SLE) susceptibility. Rheumatology (Oxford) 2007;46:1274-1276.
52. Tan SM, Xu D, Roschke V, et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003;48:982-992.
53. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002;109:59-68.
54. Hever A, Roth RB, Hevezi P, et al. Human endometriosis is associated with plasma cells and overexpression of B lymphocyte stimulator. Proc Natl Acad Sci USA 2007;104: 12451-12456.
55. Kim JY, Yang Y, Moon JS, et al. Serum BAFF expression in patients with myasthenia gravis. J Neuroimmunol 2008;199: 151-154.
56. Mackay IR, Groom J, Mackay CR. Levels of BAFF in serum in primary biliary cirrhosis and autoimmune diabetes. Autoimmunity 2002;35:551-553.
57. Cohen SB. Updates from B Cell trials: Efficacy. J Rheumatol Suppl 2006;77:12-17.
58. Kern C, Cornuel JF, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679-688.
59. Kim SJ, Lee SJ, Choi IY, et al. Serum BAFF predicts prognosis better than APRIL in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP chemotherapy. Eur J Haematol 2008;81:177-184.
60. Schwaller J, Went P, Matthes T, et al. Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's disease. Leukemia 2007;21:1324-1327.
61. Schwaller J, Schneider P, Mhawech-Fauceglia P, et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 2007;109:331-338.
62. Chiu A, Xu W, He B, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007;109:729-739.
63. Ng LG, Sutherland AP, Newton R, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004;173:807.
64. Briones J, Timmerman JM, Hilbert DM, Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 2002;30:135-141.
65. He B, Chadburn A, Jou E, et al. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004;172:3268-3279.
66. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004;103:3148-3157.
67. Novak AJ, Grote DM, Ziesmer SC, et al. Elevated serum Blymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006;24:983-987.
68. Herreros B, Sanchez-Aguilera A, Piris MA. Lymphoma microenvironment: culprit or innocent? Leukemia 2008;22: 49-58.
69. Novak AJ, Grote DM, Stenson M, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: Correlation with disease activity and patient outcome. Blood 2004;104:2247-2253.
70. He B, Raab-Traub N, Casali P, Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 2003;171:5215-5224.
71. Molica S, Digiesi G, Mauro F, et al. Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia. Leuk Res 2009;33:162-165.
72. Planelles L, Castillo-Gutierrez S, Medema JP, et al. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: Prognostic relevance of APRIL for survival. Haematologica 2007;92:1284-1285.
73. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: A mechanism for survival. Blood 2002;100: 2973-2979.
74. Caligaris-Cappio F. Role of the microenvironment in chronic lymphocytic leukaemia. Br J Haematol 2003;123:380-388.
75. Nishio M, Endo T, Tsukada N, et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1a. Blood 2005;106:1012-1020.
76. Burger JA, Tsukada N, Burger M, et al. Blood-derived nurselike cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000;96:2655-2663.
77. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathway. Blood 2007;109:703-710.
78. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333:1052-1057.
79. Smit LA, Hallaert DY, Spijker R, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007;109:1660-1668.
80. Mittal AK, Iqbal J, Nordgren TM, et al. Molecular basis of proliferation/ survival and migration of CLL in peripheral blood, bone marrow and lymph nodes [abstract]. Blood 2008;112. Abstract 546.
81. Enzler T, Widhopf GF, Lee J, et al. BAFF Accelerates development of chronic lymphocytic leukemia in TCL1 transgenic mice [abstract]. Blood 2007;110. Abstract 1117.
82. Enzler T, Zhang W, Kater AP, et al. Constitutive Baff signalling plays a key role in CLL development by promoting tumor cell survival [abstract]. Blood 2008;112. Abstract 28.
83. Planelles L, Carvalho-Pinto CE, Hardenberg G, et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 2004;6: 399-408.
84. Vanura K, Le T, Esterbauer H, et al. Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. Haematologica 2008;93:1912-1916.
85. Ekstrom SK, Vajdic CM, Falster M, et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood 2008;111:4029-4038.
86. Nimmanapalli R, Lyu MA, Du M, et al. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood 2007;109:2557-2564.